Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.

Journal: Frontiers in medicine
Published Date: Jan 15, 2025

Abstract

BACKGROUND: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy. The aim of this study is to provide the real-life anatomical-functional and safety results, after 1 year of treatment experience with Brolucizumab.

Authors

  • Settimio Rossi
    Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Carlo Gesualdo
    Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Ernesto Marano
    Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Raffaele Perrotta
    Eye Unit, G. Rummo Hospital, Benevento, Italy.
  • Maria Consiglia Trotta
    Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Antonio Del Giudice
    Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Francesca Simonelli
    Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals